Bessemer Group
BCRX icon

Bessemer Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bessemer Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Hold
278
– – ﹤0.01% 2340
2026
Q1 		$3K Hold
278
– – ﹤0.01% 2306
2025
Q4 		$2K Hold
278
– – ﹤0.01% 2395
2025
Q3 		$2K Buy
+278
New +$2.31K ﹤0.01% 2296
2025
Q1 		– Sell
-195
Closed -$1.57K – 2449
2024
Q4 		$1K Hold
195
– – ﹤0.01% 2308
2024
Q3 		$1K Sell
195
-545
-74% -$4.14K ﹤0.01% 2341
2024
Q2 		$5K Buy
+740
New +$4.08K ﹤0.01% 1675

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Bessemer Group's BCRX Position: Q2 2026 in Review

Bessemer Group held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 278 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #2340.

Bessemer Group first reported a position in BCRX in Q2 2024 and has held it in 7 quarters since. The position peaked at $5K in Q2 2024. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Bessemer Group held 278 shares of BioCryst Pharmaceuticals worth $3K as of Q2 2026.
  • Bessemer Group left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2340 holding.
  • Bessemer Group first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • Bessemer Group's BioCryst Pharmaceuticals position peaked at $5K in Q2 2024.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.